Oncologists

We’ll deliver a test report 2 days after your patient’s sample collection. That’s the industry’s fastest turnaround time for cancer therapy guidance.

Step 1 - Order the Test
Options include easy digital or fax ordering.

Step 2 - Sample Collection
We will receive the patient sample within 24 hours and processes it promptly.

Step 3 - Review results
After just two days from the sample collection, results are available to review online or via fax/paper.

In early studies, our innovative test matched the actual responses of 80% of treatments. Our predictive accuracy is being validated in multiple clinical trials.

Case Study AT025
Lung cancer patient gets a new therapy option
Testing live cancer cells of a 77-year-old male with metastatic lung cancer reveals significant mass response to Carboplatin and Etoposide.

Case Study AT031
Testing confirms response failure to genomic biomarker-directed therapy
‍Rapid Therapy Guidance test confirms the suspicion that metastatic non-small cell lung cancer with confirmed MET Exon 14 skipping mutation has stopped responding to Capmatinib.

Our lab tests a growing number of FDA-approved drugs on live tumor cells. You define a panel of up to 20 drugs per order to test.

Our drug catalog is growing, including over 100 FDA-approved drugs.

You define a panel of up to 20 drugs per order to test.

Turnaround time: 2 days from sample collection.
Sample types: Tissue, Malignant Fluids.

Each drug is scored between 0 and 100, and the list of drugs is sorted, with the highest scoring (likely effective) drugs at the top.

Simple and clear results you can leverage immediately for therapy decision-making.

The report includes graph and table of the mass change measurement data and the confidence (p-value) scores.

It explains how the scores are computed from the measurement data.

Support patients with new alternatives

While the FDA has approved many drugs to treat specific cancers, every cancer patient’s cells are unique. Late-stage cancer patients may not have the time or endurance to test multiple drugs in vivo. You can have a panel of up to 20 FDA-approved drugs tested per order. The test results will help determine which drugs or drug combinations have the potential to disrupt the growth of your patient’s cancer cells.

Improve clinical decision-making with a list of the most viable alternatives for treating your patient’s unique cancer.

Identify drugs that will be ineffective therapies and drop them from combination therapies.

Choose alternatives that are less toxic, and possibly less expensive, without compromising on efficacy.

Patient clinical outcomes show
test predictive accuracy is over 80%

In early studies, our innovative test matched the actual responses of more than 80% of treatments. Our evidence is growing through multiple clinical research studies with major medical institutions throughout the United States.

Peer-reviewed Papers

JCO Precision Oncology*
Next-generation ex vivo approaches, such as the RapidSelection™ technology, offer an alternative precision medicine approach for a broad population of patients with cancer.

Nature’s Communications Biology*
The paper describes how our technology offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient’s tumor cells.

Leading Institutions

The institutions involved in our clinical studies include:

* Links to the papers:
- Nature's Communications Biology https://www.nature.com/articles/s42003-022-04270-3
- JCO Precision Oncology https://doi.org/10.1200/PO.23.00349

Improve therapy selection

The RapidSelection™ test, you have a revolutionary tool to identify additional treatments for your cancer patients. We are moving cancer therapy beyond Standard of Care with innovative and proprietary technology developed at the Massachusetts Institute of Technology (MIT). Our test weighs individual cancer cells ex vivo with sub-picogram accuracy. Weight change begins very quickly, within a few hours of exposing the cancer cells to effective cancer drugs, and it applies to many different cancer drugs with different mechanisms of action. In an unprecedented 2-day turnaround time, you can explore alternatives for patients who have run out of options.

Personalize
Cancer
Treatments

Quickly identify more options
for personalized cancer treatments

Patient clinical outcomes show
test predictive accuracy is over 80%

Improve therapy selection

Contact us

PersonalizeCancerTreatments

Quickly identify more options for personalized cancer treatments

Patient clinical outcomes show test predictive accuracy is over 80%

Improve therapy selection

Contact us

Personalize
Cancer
Treatments

Quickly identify more options
for personalized cancer treatments

Patient clinical outcomes show
test predictive accuracy is over 80%